Epithelial Na+ channel inhibitors for the treatment of cystic fibrosis
In this patent review, brought to MedChemNet users by our sister journal Pharmaceutical Patent Analyst, the authors summarize their patent applications in regards to cystic fibrosis treatment via the inhibition of epithelial Na+ channels.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>